Evidence map›Paper›PMID 37079300›Full record

ArticleJAMA ophthalmology2023

Overlap of Genetic Loci for Central Serous Chorioretinopathy With Age-Related Macular Degeneration.

Joel T Rämö, Erik Abner, Elon H C van Dijk, Xin Wang, Joost Brinks, Tiit Nikopensius, Margit Nõukas, Heidi Marjonen, Kaisa Silander, Sakari Jukarainen and 20 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in JAMA ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. TheOphthalmology science · 2026
    Article
  6. Pachychoroid disease: review and update.Eye (London, England) · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Error in Author Affiliations.JAMA ophthalmology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 12 institutions in 4 countries.

Joel T RämöInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Erik AbnerDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Elon H C van DijkEstonian Genome Center, University of Tartu, Tartu, Estonia.
Xin WangCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Joost BrinksDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Tiit NikopensiusEstonian Genome Center, University of Tartu, Tartu, Estonia.
Margit NõukasEstonian Genome Center, University of Tartu, Tartu, Estonia.
Heidi MarjonenFinnish Institute for Health and Welfare, Helsinki, Finland.
Kaisa SilanderFinnish Institute for Health and Welfare, Helsinki, Finland.
Sakari JukarainenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Tuomo KiiskinenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Seung Hoan ChoiCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Risto KajanneInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Juha MehtonenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Priit PaltaInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Steven A LubitzCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Kai KaarnirantaDepartment of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Lucia SobrinHarvard Medical School Department of Ophthalmology, Massachusetts Eye and Ear, Boston.
Mitja KurkiInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Suzanne YzerDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
Patrick T EllinorCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Tõnu EskoDepartment of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Mark J DalyInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Anneke I den HollanderDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
Aarno PalotieInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Joni A TurunenFolkhälsan Research Center, Biomedicum, Helsinki, Finland.
Camiel J F BoonEstonian Genome Center, University of Tartu, Tartu, Estonia.
Elizabeth J RossinHarvard Medical School Department of Ophthalmology, Massachusetts Eye and Ear, Boston.
FinnGen Study
Estonian Biobank Research Team
University of Helsinki · FIInstitute for Molecular Medicine Finland · FIUniversity of Tartu · EEHarvard University · USBroad Institute · USFinnish Institute for Health and Welfare · FILeiden University Medical Center · NLRadboud University Medical Center · NLAmsterdam University Medical Centers · NLBoston University · USMassachusetts Eye and Ear Infirmary · USUniversity of Eastern Finland · FI

Funding

Mass Eye and Ear-Vision Clinical Scientist Development ProgramK12EY016335 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Reza Dana · 2004 to 2026
$12.3M
Genomics of Cardiac ArrhythmiasR01HL139731 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ELLINOR, PATRICK THOMAS · 2018 to 2022
$3.3M
Using Electrocardiogram Genetics to Inform Arrhythmia RiskR01HL157635 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ELLINOR, PATRICK THOMAS, MIRSHAHI, TOORAJ · 2022 to 2025
$2.9M
NEI NIH HHS K12 EY016335NHLBI NIH HHS R01 HL139731NHLBI NIH HHS R01 HL157635
6 · The paper itself

Abstract

Importance: Central serous chorioretinopathy (CSC) is a serous maculopathy of unknown etiology. Two of 3 previously reported CSC genetic risk loci are also associated with AMD. Improved understanding of CSC genetics may broaden our understanding of this genetic overlap and unveil mechanisms in both diseases. Objective: To identify novel genetic risk factors for CSC and compare genetic risk factors for CSC and AMD. Design, Setting, and Participants: Using International Classification of Diseases, Ninth (ICD-9) and Tenth (ICD-10) Revision code-based inclusion and exclusion criteria, patients with CSC and controls were identified in both the FinnGen study and the Estonian Biobank (EstBB). Also included in a meta-analysis were previously reported patients with chronic CSC and controls. Data were analyzed from March 1 to September 31, 2022. Main Outcomes and Measures: Genome-wide association studies (GWASs) were performed in the biobank-based cohorts followed by a meta-analysis of all cohorts. The expression of genes prioritized by the polygenic priority score and nearest-gene methods were assessed in cultured choroidal endothelial cells and public ocular single-cell RNA sequencing data sets. The predictive utility of polygenic scores (PGSs) for CSC and AMD were evaluated in the FinnGen study. Results: A total of 1176 patients with CSC and 526 787 controls (312 162 female [59.3%]) were included in this analysis: 552 patients with CSC and 343 461 controls were identified in the FinnGen study, 103 patients with CSC and 178 573 controls were identified in the EstBB, and 521 patients with chronic CSC and 3577 controls were included in a meta-analysis. Two previously reported CSC risk loci were replicated (near CFH and GATA5) and 3 novel loci were identified (near CD34/46, NOTCH4, and PREX1). The CFH and NOTCH4 loci were associated with AMD but in the opposite direction. Prioritized genes showed increased expression in cultured choroidal endothelial cells compared with other genes in the loci (median [IQR] of log 2 [counts per million], 7.3 [0.6] vs 4.7 [3.7]; P = .004) and were differentially expressed in choroidal vascular endothelial cells in single-cell RNA sequencing data (mean [SD] fold change, 2.05 [0.38] compared with other cell types; P < 7.1 × 10-20). A PGS for AMD was predictive of reduced CSC risk (odds ratio, 0.76; 95% CI, 0.70-0.83 per +1 SD in AMD-PGS; P = 7.4 × 10-10). This association may have been mediated by loci containing complement genes. Conclusions and Relevance: In this 3-cohort genetic association study, 5 genetic risk loci for CSC were identified, highlighting a likely role for genes involved in choroidal vascular function and complement regulation. Results suggest that polygenic AMD risk was associated with reduced risk of CSC and that this genetic overlap was largely due to loci containing complement genes.

Indexed as

Central Serous ChorioretinopathyMacular DegenerationEndothelial CellsFemaleGenetic BackgroundGenetic LociGenome-Wide Association StudyHumans

Identifiers

PMID37079300
PMCPMC10119776
OpenAlexW4366463044

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.